PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Drug side effects

nortriptyline Side Effects

The reactions most often reported to the FDA for nortriptyline (also sold as Pamelor), with demographics, serious outcomes, and reporting trends.

Data updated 2026-05-15

5,503
FAERS reports

Data from the FDA Adverse Event Reporting System (FAERS), 2004 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.

The most commonly reported side effects of nortriptyline come from 5,503 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.

This page analyzes 5,503 reports to the FDA Adverse Event Reporting System (FAERS) for nortriptyline (Pamelor): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.

Total Reports

5,503

Reports Mentioning Death

674

12.2% of reports — not proof the medicine caused the death

Hospitalizations

1,439

26.1% of reports

Top Indication

Product Used For Unknown Indication

Most Reported Adverse Reactions

PAIN
695
HEADACHE
679
FATIGUE
593
NAUSEA
513
HYPERHIDROSIS
485
HYPERSENSITIVITY
460
DRUG HYPERSENSITIVITY
430
HYPERTENSION
396
CONSTIPATION
395
RHEUMATOID ARTHRITIS
388
HEPATIC ENZYME INCREASED
383
OVERDOSE
374
BACK PAIN
365
JOINT SWELLING
361
IMMUNODEFICIENCY
358
UPPER RESPIRATORY TRACT INFECTION
351

Who Reports Side Effects

Gender Distribution

Female 3,671 (75%)
Male 1,179 (24%)
Unknown 14

Age Distribution

0-17 53 (2%)
18-44 852 (26%)
45-64 1,575 (48%)
65-74 500 (15%)
75+ 292 (9%)

Reporting Trend by Year

2004 2025

Reactions in Death Reports

Top reactions reported in 674 reports where death was an outcome. These are voluntarily reported and do not establish causation.

Reaction Reports
COMPLETED SUICIDE 203
OVERDOSE 131
PAIN 110
TOXICITY TO VARIOUS AGENTS 110
HYPERTENSION 105
PYREXIA 104
THROMBOCYTOPENIA 104
FATIGUE 103
CONSTIPATION 101
PSORIASIS 101
DEATH 100
UPPER RESPIRATORY TRACT INFECTION 99
CONTRAINDICATED PRODUCT ADMINISTERED 98
HEADACHE 98
HYPERHIDROSIS 98
TEMPERATURE REGULATION DISORDER 98

Reactions in Hospitalization Reports

Top reactions in 1,439 reports where hospitalization was an outcome.

Reaction Reports
SOMNOLENCE 226
GASTROOESOPHAGEAL REFLUX DISEASE 214
COMA 199
PNEUMONIA ASPIRATION 195
PAIN 175
NAUSEA 170
FATIGUE 148
DIARRHOEA 146
FALL 133
PAIN IN EXTREMITY 129
HEADACHE 117
ARTHRALGIA 102
SLEEP DISORDER 99
OSTEOARTHRITIS 96
DEPRESSION 92
OSTEOPENIA 90
DYSPNOEA 89
DIZZINESS 88

Compare nortriptyline vs acamprosate →

What the FAERS Data Reveals About nortriptyline Side Effects

The FDA Adverse Event Reporting System (FAERS) contains 5,503 voluntary reports linked to nortriptyline and its brand equivalents (Pamelor), spanning 2004 through 2025. Of those, 674 (12.2%) listed death as an outcome and 1,439 (26.1%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.

Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 75% were female and 24% male; age distribution skews toward 45-64, with 1,575 reports in that bracket. The single most reported reaction is pain with 695 submissions, followed by headache and fatigue.

How to read these numbers

FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.